Hepatorenal syndrome epidemiology and demographics
|
Hepatorenal syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatorenal syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatorenal syndrome epidemiology and demographics |
|
Hepatorenal syndrome epidemiology and demographics in the news |
|
Risk calculators and risk factors for Hepatorenal syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology and Demographics
It is estimated that 39% of patients with cirrhosis and ascites will develop hepatorenal syndrome within five years of the onset of their disease. The prognosis of these patients is grim with untreated patients having an extremely short survival, and with the severity of liver disease (as evidenced by the MELD score) now believed to determine outcome.[1] Some patients without cirrhosis develop hepatorenal syndrome, with an incidence of about 20% seen in one study of ill patients with alcoholic hepatitis.[2]
References
- ↑ Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology 2005 Jun;41(6):1282-9. PMID 15834937
- ↑ Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 Dec;119(6):1637-48. PMID 11113085.